Summary. Premerger notification is a procedural statute with substantive consequences, and the most common failures are administrative: a filing that was required and not made, a document that should have been produced and was not, or conduct between signing and closing treated as an unlawful transfer of control. This article covers the two jurisdictional tests, the exemptions, and the valuation rules that make small transactions reportable. It works through the filing, the Item 4(c) and 4(d) production that drives substantive review, the waiting period, and second requests — then § 7 analysis, remedies, gun jumping, interlocking directorates, and non-reportable deals agencies still challenge.

A private equity fund acquires a regional distributor for $92 million. Counsel confirms the transaction is reportable, prepares the filing, and clears the waiting period.

Eight months later the same fund's operating partner acquires an additional block of voting securities in a public company the fund already partly owns, bringing the fund's holdings from 4.2 percent to 6.1 percent. Nobody files, because the fund holds well under ten percent and the purchase was made on the open market for $58 million.

That was a violation. The size-of-transaction threshold is met, the ten percent "investment only" exemption requires that the acquirer have no intention of participating in the basic business decisions of the issuer — and the fund's operating partner had already had two conversations with management about board representation.

The civil penalty for failing to file accrues per day for each day of noncompliance, at a rate adjusted annually for inflation, and the eight-month exposure is arithmetically enormous. The agency will typically resolve a first, self-reported, non-egregious violation with a corrective filing and no penalty — but the analysis of whether the violation was inadvertent turns on facts nobody was tracking.

HSR is a statute where the answer is usually "no filing required," and where the cost of getting the exception wrong is measured in days.

The short answer

The statute. Section 7A of the Clayton Act, 15 U.S.C. § 18a, added by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and the implementing rules at 16 C.F.R. parts 801-803.

What it requires. Parties to a reportable acquisition of voting securities, non-corporate interests, or assets must file with both the FTC and the Antitrust Division and wait before closing.

The waiting period is 30 days for most transactions (15 days for a cash tender offer or a bankruptcy sale under 11 U.S.C. § 363(b)).

The two tests, both adjusted annually and both of which must be considered:

  1. Size of transaction — the value of the voting securities, non-corporate interests, or assets held as a result of the acquisition must exceed the current threshold.
  2. Size of person — where the transaction value falls in the middle band, one person must have annual net sales or total assets above a larger threshold and the other above a smaller one. Above the upper transaction threshold, the size-of-person test does not apply.

Confirm the current thresholds before relying on any figure. They are revised each year based on changes in gross national product, and filing fee tiers were restructured and are also indexed.

The most important practical point: HSR is a notification statute. Clearing the waiting period does not immunize a transaction. The agencies may challenge a consummated merger at any time under § 7 of the Clayton Act, and they do.

Who files, and on what

The acquiring person and the acquired person each file. "Person" means the ultimate parent entity (UPE) — the entity not controlled by any other entity — and everything it controls. Control means holding 50 percent or more of the voting securities of a corporation, or having the contractual power to designate 50 percent or more of the directors, or holding a right to 50 percent or more of the profits or assets on dissolution of a non-corporate entity.

Identifying the UPE is the first analytical step and is frequently harder than it sounds: a fund structure with parallel vehicles, a family trust, an individual holding entities in a personal capacity, or a joint venture with no controlling parent each require careful work under the rules.

What is acquired:

  • Voting securities — securities conferring the present right to vote for directors.
  • Non-corporate interests — LLC and partnership interests, reportable only where the acquisition confers control (50 percent or more of profits or assets on dissolution).
  • Assets, including intangible assets and exclusive licenses of intellectual property, which are treated as asset acquisitions under the rules.

"Held as a result of." The test aggregates what the acquirer will hold after the transaction, not what it is buying now. An acquirer holding $80 million of an issuer's stock that buys another $40 million is tested on $120 million. This is the rule that catches serial open-market purchasers.

Notification thresholds for voting securities. After a filing, the acquirer may cross the notified threshold and continue acquiring up to the next threshold for five years without a new filing. The thresholds are set at defined dollar levels and at 25 percent and 50 percent of an issuer's voting securities. Crossing a higher threshold requires a new filing.

Valuation

Acquisition price governs where it is determined. Where it is not — an open market purchase, a contingent price, an asset acquisition with an undetermined price — the acquiring person's board (or its delegee) must determine the fair market value in good faith, within 60 days before filing.

Elements that must be included and are commonly missed:

  • Assumed liabilities, in an asset acquisition, to the extent they constitute consideration.
  • Contingent consideration and earnouts, valued in good faith.
  • Prior acquisitions from the same acquired person within the applicable look-back, which are aggregated under the rules.
  • Voting securities already held by the acquiring person.
  • Value of non-corporate interests already held where control is being acquired.

Exclusions that reduce value: cash consideration that is not part of the acquisition price under the rules, and certain assets that are separately exempt.

Exemptions

Most transactions that meet the size tests are still not reportable, because an exemption applies. The frequently used ones:

  • Ordinary course of business, 16 C.F.R. § 802.1 — acquisitions of current supplies and, in defined circumstances, used durable goods. This exemption is narrower than its name suggests and does not cover an acquisition of an operating business.
  • Acquisitions of goods and realty in the ordinary course, and certain new goods acquisitions.
  • Investment-only, § 802.9 — acquisitions of 10 percent or less of an issuer's voting securities solely for the purpose of investment, meaning no intention of participating in the formulation, determination, or direction of the basic business decisions of the issuer. Conduct inconsistent with passivity — seeking board representation, nominating directors, proposing a transaction, soliciting proxies for a change of control, or having a competitively significant relationship — defeats it. Institutional investors have a separate, somewhat broader exemption at § 802.64.
  • Acquisitions of foreign assets and foreign issuers, §§ 802.50-802.51, where US sales or assets attributable to the target fall below thresholds.
  • Real property exemptions, §§ 802.2-802.5, covering new facilities, used facilities, unproductive real property, office and residential property, hotels, and investment rental property — subject to conditions.
  • Intraperson transactions, § 802.30, between entities within the same person.
  • Acquisitions by creditors in a bona fide credit transaction and certain foreclosures.
  • § 802.4 — an acquisition of voting securities or non-corporate interests of an entity whose non-exempt assets fall below the size-of-transaction threshold. This exemption does substantial work in real estate and holding-company structures.

Exemption analysis is technical and unforgiving. The FTC's Premerger Notification Office provides informal interpretations, and the practice of calling the PNO with a factual scenario is well established and genuinely useful — though informal advice is not binding.

The filing

The form. Each party files a Notification and Report Form. The FTC substantially expanded the form's requirements, adding narrative descriptions of the transaction rationale, competitive overlaps and supply relationships, organizational structure and minority holders, prior acquisitions, and additional document categories. The practical consequence is that preparation time has moved from days to weeks, and the burden falls disproportionately on the acquiring party.

Item 4(c) and 4(d) documents are the heart of the substantive review. Item 4(c) requires all studies, surveys, analyses, and reports prepared by or for officers or directors for the purpose of evaluating or analyzing the acquisition with respect to market shares, competition, competitors, markets, or expansion into product or geographic markets. Item 4(d) reaches confidential information memoranda, materials prepared by third-party advisors, and synergy and efficiency analyses.

What this means in practice. The bankers' deck describing the target as "the number two player in a consolidating market" and projecting "pricing improvement post-integration" is an Item 4(c) document. So is the internal memorandum saying the acquisition will "eliminate our most aggressive competitor." Those documents drive second requests more than any market share calculation, because they are the parties' own characterization of the deal.

The discipline that follows is unglamorous and important: train deal teams before diligence begins on how to describe a transaction. Not to conceal — concealment is a separate and far worse problem — but to describe the rationale accurately. A synergy analysis quantifying cost savings is fine. A slide asserting that the combination will let the company "raise prices without losing share" is a problem, and it is usually not even true.

The filing fee is paid by the acquiring person, on a tiered schedule indexed annually to transaction value. Confirm the current tiers.

Where and how. Both agencies receive the filing, now through an electronic filing system. The acquired person's filing is shorter for a public target and can be prepared quickly; the acquiring person's filing carries the document production burden.

Timing. The waiting period begins when both parties have filed. In a hostile transaction or an open market purchase, the acquiring person may file unilaterally, and the target must respond within a defined period.

The waiting period and second requests

Thirty days, or fifteen for a cash tender offer or a § 363 bankruptcy sale.

Early termination. The agencies suspended granting early termination and the practice has been used sparingly since. Plan on the full period.

Pull and refile. A party may withdraw its filing and refile within two business days without a new fee, restarting a fresh 30-day period. This is the standard mechanism for giving the reviewing agency more time to complete its analysis and avoid issuing a second request. It is voluntary, common, and usually preferable to a second request by a wide margin.

The second request. If the reviewing agency needs more information, it issues a Request for Additional Information and Documentary Material. The consequences are substantial:

  • The waiting period is extended until 30 days after both parties substantially comply (10 days for a cash tender offer).
  • Compliance typically requires production of millions of documents from dozens of custodians, structured data, interrogatory-style narrative responses, and privilege logs.
  • Cost commonly runs into the millions of dollars and several months of elapsed time.
  • The agency also takes investigational hearings — sworn testimony from company witnesses — and interviews customers and competitors, whose views frequently determine the outcome.

Managing a second request:

  • Negotiate the scope immediately. Agencies routinely narrow custodians, date ranges, and specifications, and the negotiation is expected.
  • Enter a timing agreement — a commitment not to certify compliance before a date and not to close for a stated period after certification, in exchange for narrowing. These are now standard.
  • Preserve everything from the moment a second request is anticipated.
  • Prepare witnesses carefully for investigational hearings.
  • Advocate affirmatively: a white paper explaining market definition, entry, expansion, efficiencies, and customer views, supported by economists, is the mechanism for closing an investigation without litigation.

Outcomes. The agency closes the investigation; the parties agree to a consent decree with divestitures or conduct remedies; the parties abandon; or the agency sues to enjoin.

The substantive standard

Section 7 of the Clayton Act, 15 U.S.C. § 18, prohibits acquisitions where the effect "may be substantially to lessen competition, or to tend to create a monopoly." It is an incipiency standard — the agencies need not show that harm has occurred or is certain.

The current merger guidelines, issued jointly by the agencies, describe the frameworks used to assess mergers. The analysis typically proceeds through:

  • Market definition — a relevant product and geographic market, often tested with the hypothetical monopolist test, though the guidelines also contemplate direct evidence of competitive effects without a formally defined market.
  • Concentration — measured by the Herfindahl-Hirschman Index, with structural presumptions of illegality at defined concentration levels and increases. United States v. Philadelphia National Bank, 374 U.S. 321 (1963), supplies the structural presumption, which the guidelines apply at thresholds lower than those used in earlier iterations.
  • Theories of harm — unilateral effects (loss of head-to-head competition between close substitutes), coordinated effects (increased likelihood of tacit or express coordination), foreclosure of rivals' access to inputs or customers in vertical transactions, elimination of a potential entrant, a serial acquisition strategy assessed cumulatively, and effects in labor markets.
  • Rebuttal — entry that is timely, likely, and sufficient; efficiencies that are merger-specific, verifiable, and passed through; and the failing firm defense, which is narrow and requires grave probability of business failure, inability to reorganize, unsuccessful good-faith efforts to find alternative purchasers, and the absence of a less anticompetitive alternative.

Vertical mergers. The agencies withdrew the separate 2020 vertical merger guidelines, and vertical theories are now addressed within the unified guidelines, focused on foreclosure, raising rivals' costs, and access to competitively sensitive information.

Litigation results have been mixed, and several agency challenges have failed in court, which affects the credible threat behind a second request. Nonetheless, the practical constraint on most transactions is not the risk of losing at trial; it is the cost, delay, and deal-jeopardy of a full investigation.

Remedies

Structural remedies — divestiture of a business, asset package, or brand — remain the agencies' preference, because they restore the competitive structure without ongoing supervision. Requirements that determine whether a divestiture will be accepted: the package must be a standalone, viable business, not a collection of assets; the buyer must be approved and must have the capability and incentive to compete; and an upfront buyer is frequently required before the agency will accept the remedy.

Conduct remedies — firewalls, non-discrimination commitments, supply obligations, and licensing requirements — have fallen out of favor, on the view that they require ongoing regulation of a market the agency is not equipped to supervise. They appear more often in vertical cases and in settlements with state attorneys general.

Hold separate and asset preservation obligations apply between agreement and divestiture.

Non-compliance with a consent decree carries civil penalties and the possibility of a court-appointed divestiture trustee.

Deal protection. Where regulatory risk is material, the merger agreement's risk allocation matters as much as the antitrust analysis: the efforts standard for obtaining clearance (reasonable best efforts, or a "hell or high water" covenant requiring the buyer to divest whatever is necessary), a divestiture cap, a regulatory reverse termination fee, the outside date and extension mechanics, and control of the regulatory strategy and communications.

Gun jumping

Between signing and closing, the parties remain independent competitors, and conduct that transfers beneficial ownership or coordinates competitive behavior violates HSR's waiting period requirement and, independently, § 1 of the Sherman Act.

What is prohibited:

  • The buyer directing the seller's pricing, output, bidding, or customer decisions.
  • Joint decisions on contracts, promotions, or terms with customers before closing.
  • Exchanging competitively sensitive information — current and forward-looking pricing, customer-specific terms, bids, costs, strategic plans, and unaggregated wage data — outside appropriate protections.
  • Allocating customers or territories in anticipation of closing.
  • The buyer assuming operational control of the seller's business.

What is permitted:

  • Ordinary due diligence, with sensitive information handled through a clean team of individuals not involved in competitive decision-making, subject to a written protocol.
  • Covenants in the merger agreement requiring the seller to operate in the ordinary course and restricting extraordinary actions — including material contracts, capital expenditures above thresholds, and equity issuances — which are conventional and lawful.
  • Integration planning conducted through a clean team, with implementation deferred to closing.
  • Joint communications with regulators, and coordinated planning for customer and employee communications to be delivered after closing.

Penalties include the per-day civil penalty for the HSR violation and, for information exchange amounting to an agreement, Sherman Act exposure with treble damages. Both agencies have brought gun-jumping cases, and the facts are usually documented in emails between operating teams who had no idea a rule applied.

The practical control is a short, written pre-closing conduct protocol distributed to everyone touching the transaction, plus a clean team agreement and a named gatekeeper for any information request that touches price, customers, or costs.

Interlocking directorates and non-reportable transactions

Section 8 of the Clayton Act, 15 U.S.C. § 19, prohibits a person from serving simultaneously as an officer or director of two competing corporations above statutory size and de minimis thresholds, which are adjusted annually. It is a per se prohibition requiring no proof of anticompetitive effect. The Antitrust Division has enforced § 8 actively in recent years, obtaining board resignations across portfolio companies of private equity and venture funds — a reminder that a fund partner sitting on two boards in the same space is a live issue even where no transaction is contemplated. The prohibition reaches interlocks accomplished through deputization, where different individuals from the same firm serve on competing boards.

Non-reportable transactions remain subject to challenge. Nothing about falling below the HSR thresholds immunizes an acquisition. The agencies have pursued consummated, non-reportable deals — including in healthcare, waste services, and technology — sometimes years after closing, and have sought divestiture. State attorneys general have parallel authority, and several states have enacted their own premerger notification statutes requiring filings for healthcare transactions or for transactions affecting the state regardless of federal reportability.

Private challenges. A competitor or customer with antitrust injury may sue under § 16 of the Clayton Act for injunctive relief and may seek damages under § 4. Private merger challenges are rare and occasionally successful.

The practical conclusion for a small transaction: the HSR analysis answers whether a filing is required, and a separate substantive analysis answers whether the deal creates antitrust risk. In a consolidating local market — hospitals, funeral homes, veterinary practices, waste hauling, dialysis — a $30 million transaction can present more genuine risk than a $500 million transaction between firms that do not compete.

A worked example

Cardinal Fluid Systems agrees to acquire Brightwater Controls for $340 million. Both make industrial flow control valves; they overlap in one product line representing about 12 percent of the combined revenue.

Week 1. Counsel confirms reportability: the transaction value exceeds the threshold, and the size-of-person test is inapplicable above the upper threshold. Counsel also runs a substantive assessment: in the overlapping line, the combined share is roughly 38 percent with two other significant competitors and low entry barriers for adjacent manufacturers.

Week 2. Counsel reviews the deal documents already created. The banker's deck contains a slide titled "Rationalizing a Fragmented Category" with a bullet reading "removes the primary price aggressor." Counsel flags it as an Item 4(c) document that must be produced and prepares to address it — not by suppressing it, but by building the record showing that the characterization was a banker's shorthand contradicted by the company's own win-loss data.

Week 3. Merger agreement negotiated with antitrust risk allocated: reasonable best efforts, a divestiture obligation capped at businesses representing up to $25 million of revenue, a $14 million regulatory reverse termination fee, an outside date nine months out with two three-month extensions, and buyer control of regulatory strategy with seller consultation rights.

Week 4. A pre-closing conduct protocol and clean team agreement are circulated. Pricing, customer-specific terms, and bid data go only to three clean team members and outside economists.

Week 6. Both parties file. Waiting period begins.

Week 9. The FTC opens a preliminary investigation and asks for a voluntary submission on the overlapping line. The parties pull and refile, giving the staff another 30 days, and submit a white paper with win-loss data showing the parties are not each other's closest substitutes, plus customer contacts who confirm alternative suppliers.

Week 13. The waiting period expires without a second request. The transaction closes.

What made the difference: identifying the overlap in week one rather than at filing; addressing the problematic document affirmatively rather than hoping it would not be read; choosing pull-and-refile over the risk of a second request; and having customer evidence ready before staff called the customers themselves.

A timeline checklist

Before the LOI

  • Identify overlaps — product, geographic, and labor — and any vertical relationship.
  • Run a preliminary HSR reportability analysis, including UPE identification.
  • Assess substantive risk independently of reportability.
  • Brief the deal team on document discipline and what an Item 4(c) document is.

During negotiation

  • Allocate regulatory risk: efforts standard, divestiture cap, reverse termination fee, outside date, and strategy control.
  • Put a pre-closing conduct protocol and clean team agreement in place before diligence begins.
  • Confirm valuation inputs: assumed liabilities, earnouts, prior acquisitions, and existing holdings.

Filing

  • Confirm current thresholds and fee tiers.
  • Determine the UPE for each party, and collect the organizational, revenue, and prior-acquisition data the expanded form requires.
  • Collect and review Item 4(c) and 4(d) documents from every officer and director, including materials held by advisors.
  • Consider a voluntary submission or advocacy white paper where an overlap exists.
  • File; the waiting period runs from the later filing.

During the waiting period

  • Do not integrate, coordinate, or exchange sensitive information outside the clean team.
  • Respond promptly to voluntary requests.
  • Consider pull and refile if staff needs more time.
  • Prepare customers and, where appropriate, arrange for them to speak with staff.

If a second request issues

  • Negotiate scope and enter a timing agreement.
  • Preserve broadly and immediately.
  • Build the economic case and prepare witnesses.
  • Evaluate remedies early, and identify an upfront buyer if divestiture is likely.

Ongoing, deal or no deal

  • Audit board seats for § 8 interlocks across affiliates and portfolio companies.
  • Track serial acquisitions in a single space, which are assessed cumulatively.
  • Check for state premerger filing obligations, particularly in healthcare.

Frequently asked questions

Our deal is below the threshold. Are we safe? From the filing obligation, yes. From antitrust challenge, no. The agencies and state attorneys general challenge non-reportable transactions, sometimes years later.

Can we close if the waiting period expires and nobody objected? Yes, and the agencies may still sue afterward. Expiration is not approval.

How long does a second request take? Typically six months to more than a year from issuance to resolution, depending on scope, negotiation, and whether litigation follows.

What is a pull and refile? Withdrawing and refiling within two business days to restart a fresh 30-day period without a new fee. It is voluntary, standard, and usually preferable to a second request.

Do we have to produce the banker's deck? If it was prepared for an officer or director for the purpose of evaluating the acquisition with respect to markets or competition, yes. Failing to produce responsive documents is a far worse problem than the documents themselves.

Can we start integration planning before closing? Planning, yes, through a clean team with a written protocol. Implementing, no.

Can our CEO sit on the board of a company we compete with? Not if both corporations exceed the § 8 thresholds and the competitive sales de minimis exception does not apply. The prohibition is per se and is being actively enforced.

We are buying 8 percent of a public competitor as an investment. Reportable? Possibly exempt under § 802.9 — but only if the acquisition is solely for investment, meaning no intention of participating in basic business decisions. Any board discussion, nomination, or activist step defeats it, and a competitive relationship makes the exemption harder to rely on.

Conclusion

Hart-Scott-Rodino is a scheduling statute wrapped around a substantive review, and the two failure modes are entirely different.

The procedural failure — a missed filing, an unproduced document, a gun-jumping email — is unforced and expensive, and it is prevented by identifying the ultimate parent entities early, valuing the transaction correctly, collecting Item 4(c) documents from everyone who has one, and circulating a pre-closing conduct protocol before diligence begins.

The substantive failure is a deal that should have been analyzed for competitive effects at the letter of intent and was analyzed at the filing instead. By then the banker's deck exists, the strategic rationale is documented in the parties' own words, and the options have narrowed to divestiture, abandonment, or litigation.

The work that prevents both is done in the first two weeks, before anyone has spent real money.

Foreign and sector-specific review

HSR is one clearance among several, and a transaction that clears the FTC can still be blocked or delayed elsewhere.

Foreign merger control. More than a hundred jurisdictions operate merger regimes, most with mandatory, suspensory filings triggered by local turnover or asset thresholds that bear no relationship to where the transaction was negotiated. The European Union's system applies EU-wide turnover tests with a one-stop-shop principle; the United Kingdom's regime is formally voluntary but the Competition and Markets Authority can and does investigate unnotified deals and impose hold-separate orders; China's regime has been the source of substantial delay in transactions with modest China revenue. For any deal with meaningful international revenue, the filing analysis should run in parallel with HSR from week one, because the longest clearance timeline determines the closing date, and several regimes measure review periods in phases that can extend well beyond a year.

CFIUS. The Committee on Foreign Investment in the United States reviews transactions that could result in foreign control of a US business, and, under the expanded authority of the Foreign Investment Risk Review Modernization Act, certain non-controlling investments in businesses involved in critical technology, critical infrastructure, or sensitive personal data, plus real estate transactions near sensitive facilities. Filings are mandatory in defined circumstances — including where a foreign government holds a substantial interest — and voluntary otherwise, though a voluntary filing buys a safe harbor that an unfiled transaction lacks. CFIUS can require mitigation agreements, order divestiture of a completed transaction, and has no statute of limitations for non-notified deals.

Team Telecom reviews transactions involving FCC licenses with foreign ownership, and the FCC itself must approve license transfers.

Sector regulators. Banking transactions require Federal Reserve, OCC, or FDIC approval; insurance requires state department approval under Form A change-of-control procedures in every state where the insurer is licensed; healthcare transactions increasingly require state attorney general or health department review under state-specific notice statutes; energy transactions may require FERC approval; and transportation, defense, and gaming each have their own regimes.

Practical sequencing. Build a single regulatory calendar at signing listing every required filing, the trigger, the responsible party, the preparation time, and the statutory review period. Then set the outside date from the longest path, not the shortest, and negotiate extension mechanics that reflect it. Deals fail on outside dates far more often than they fail on the merits of a regulator's objection.

Common filing errors

The Premerger Notification Office's informal interpretations and the agencies' enforcement actions point at the same recurring mistakes.

  • Misidentifying the ultimate parent entity. Filing in the name of the operating subsidiary rather than the UPE, or missing that a fund's general partner or a family trust sits at the top of the structure. The filing is then defective and the waiting period does not run.
  • Ignoring the "held as a result of" rule. Testing only the securities being purchased rather than everything the acquirer will hold afterward, which is how incremental open-market purchases become violations.
  • Overlooking assumed liabilities in an asset acquisition, which are part of the acquisition price and frequently push a transaction over the threshold.
  • Missing that an exclusive license is an asset acquisition. An exclusive license of intellectual property within a therapeutic or field-of-use area is treated as an asset transfer under the rules, and pharmaceutical and technology licensing deals are reportable more often than the parties expect.
  • Relying on the investment-only exemption while acting like an owner. Any step toward board representation, a proposal to management, or a competitively significant relationship defeats it.
  • Forgetting the acquired person's obligation. In a hostile or open-market acquisition the target must file, and a target that ignores the notice creates a problem for itself.
  • Incomplete Item 4(c) collection. Searching only the deal folder rather than every officer's and director's files, including personal email and messaging where used for business, and omitting advisor-prepared materials.
  • Failing to re-file on crossing a higher notification threshold, or letting the five-year window expire and continuing to acquire.
  • Consummating before the period expires, including through a partial closing, an escrow arrangement that transfers beneficial ownership, or an early transfer of operational control.
  • Treating an intraperson reorganization as reportable, or the reverse — assuming a restructuring is exempt without confirming the control analysis.

When a violation is discovered. The correct response is prompt, voluntary disclosure through counsel, a corrective filing, and an explanation of how it happened and what controls now prevent recurrence. Agencies have historically declined to seek penalties for a first, inadvertent, promptly corrected violation, and have sought substantial penalties for repeat violations and for failures that were not self-reported. The worst outcome is discovery by the agency in the course of reviewing a later transaction, which is how a great many of them come to light.

Related articles

This article is provided for general informational purposes and does not constitute legal advice. HSR thresholds, filing fees, and form requirements are revised regularly, and merger enforcement policy changes with administrations. Consult qualified antitrust counsel before signing a transaction agreement or acquiring voting securities.